10 (11) 11 (22) 8 (16) 27 (19) 18 (13) Febrile neutropenia 5 (5) 5 (5) 3 (6) 3 (6) 8 (6) 8 (6) Non-hematological toxicities Nausea 84 (89) 18 (19) 44 (88) 7 (14) 128 (89) (88) 27 (29) 46 (92) 10 (20) 129 (90) 37 (26) Fatigue 69 (73) 5 (5) 26 (52) 4 (8) 95 (66) 9 (6) Peripheral neuropathy 28 (30) 2 (2) 10 (20) -
The target population of the AVAGAST study was metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastroesophageal junction b The target population of the ToGA study was HER2-positive metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction
